Celldex Therapeutics, Inc.
CLDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $2 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $2 | $2 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 2% | 192% | -49.3% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,229.8% | -1,614.5% | -3,389.9% | -1,046.2% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,733.6% | -2,020% | -4,420.9% | -1,420.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,248.8% | -2,054.8% | -4,765.6% | -1,516% |
| EPS Diluted | -2.45 | -2.92 | -2.4 | -1.64 |
| % Growth | 16.1% | -21.7% | -46.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |